BNP Paribas Financial Markets
CUE icon

BNP Paribas Financial Markets’s Cue Biopharma CUE Stock Holding History

BNP Paribas Financial Markets’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Hold
14
– – ﹤0.01% 5687
2025
Q4 		$127 Sell
14
-9
-39% -$165 ﹤0.01% 5595
2025
Q3 		$496 Sell
23
-1
-4% -$23 ﹤0.01% 5311
2025
Q2 		$488 Hold
24
– – ﹤0.01% 5228
2025
Q1 		$651 Sell
24
-4
-14% -$149 ﹤0.01% 5114
2024
Q4 		$931 Buy
28
+1
+4% +$38 ﹤0.01% 5093
2024
Q3 		$606 Hold
27
– – ﹤0.01% 3989
2024
Q2 		$993 Sell
27
-571
-95% -$28.2K ﹤0.01% 3868
2024
Q1 		$33.9K Buy
598
+41
+7% +$2.89K ﹤0.01% 3606
2023
Q4 		$44.2K Sell
557
-166
-23% -$11.9K ﹤0.01% 3587
2023
Q3 		$49.9K Buy
723
+420
+139% +$41K ﹤0.01% 3469
2023
Q2 		$33.2K Buy
303
+300
+10,000% +$35.3K ﹤0.01% 3548
2023
Q1 		$346 Sell
3
-3
-50% -$286 ﹤0.01% 3737
2022
Q4 		$542 Hold
6
– – ﹤0.01% 3853
2022
Q3 		$424 Sell
6
-115
-95% -$9.89K ﹤0.01% 4541
2022
Q2 		$9.02K Sell
121
-126
-51% -$14.7K ﹤0.01% 3757
2022
Q1 		$36.1K Sell
247
-463
-65% -$98.2K ﹤0.01% 3614
2021
Q4 		$241K Buy
710
+522
+278% +$202K ﹤0.01% 3323
2021
Q3 		$82.1K Buy
188
+153
+437% +$53.4K ﹤0.01% 3350
2021
Q2 		$12.3K Sell
35
-89
-72% -$34.5K ﹤0.01% 3669
2021
Q1 		$45.2K Buy
124
+7
+6% +$2.88K ﹤0.01% 3636
2020
Q4 		$43.9K Sell
117
-111
-49% -$44.4K ﹤0.01% 3617
2020
Q3 		$103K Buy
228
+147
+181% +$84.7K ﹤0.01% 3099
2020
Q2 		$59.9K Sell
81
-124
-60% -$89.8K ﹤0.01% 2962
2020
Q1 		$87.5K Buy
205
+118
+136% +$57.2K ﹤0.01% 3270
2019
Q4 		$41.3K Sell
87
-11
-11% -$3.46K ﹤0.01% 3740
2019
Q3 		$24.8K Buy
98
+29
+42% +$6.97K ﹤0.01% 3855
2019
Q2 		$18.5K Sell
69
-58
-46% -$14.4K ﹤0.01% 3921
2019
Q1 		$29.4K Buy
127
+117
+1,170% +$22.3K ﹤0.01% 3783
2018
Q4 		$1.42K Sell
10
-9
-47% -$1.63K ﹤0.01% 3867
2018
Q3 		$5.14K Sell
19
-1
-5% -$289 ﹤0.01% 4047
2018
Q2 		$7.17K Sell
20
-38
-66% -$15.1K ﹤0.01% 3937
2018
Q1 		$24.4K Buy
+58
New +$26.4K ﹤0.01% 3869

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

BNP Paribas Financial Markets's CUE Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Cue Biopharma (CUE) position steady in Q1 2026 at 14 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #5687.

BNP Paribas Financial Markets first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $241K in Q4 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • BNP Paribas Financial Markets held 14 shares of Cue Biopharma worth $95 as of Q1 2026.
  • BNP Paribas Financial Markets left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5687 holding.
  • BNP Paribas Financial Markets first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • BNP Paribas Financial Markets's Cue Biopharma position peaked at $241K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.